Korean J Gastroenterol.  2014 May;63(5):329-332. 10.4166/kjg.2014.63.5.329.

Is HBsAg Loss an Ideal End-point of Oral Antiviral Therapy in Chronic Hepatitis B Patients?

Affiliations
  • 1Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. kjhhepar@naver.com

Abstract

No abstract available.


MeSH Terms

Antiviral Agents/*therapeutic use
Carcinoma, Hepatocellular/*virology
Female
Hepatitis B Surface Antigens/*blood
Hepatitis B, Chronic/*blood/*drug therapy
Humans
Liver Neoplasms/*virology
Male
Antiviral Agents
Hepatitis B Surface Antigens
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr